Skip to main content

Table 1 Effect of 17-AAG on tumour volume

From: Effects of HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) on NEU/HER2 overexpressing mammary tumours in MMTV-NEU-NT mice monitored by Magnetic Resonance Spectroscopy

  Tumour volume (% of day 0) at day 4 (N) P compared to day 0 Tumour volume (% of control) at day 4) P compared to Control at day 4
Control 128.4 ± 5.9 (11) 0.0007   
17-AAG (20mg/kg) 88.5 ± 2.9 (11) 0.003 68.9% <0.0001
17-AAG (40mg/kg) 67.0 ± 3.6 (10) <0.0001 52.2% <0.0001
17-AAG (80mg/kg) 42.1 ± 7 (6) 0.0004 32.8% <0.0001
  1. Effect of 3 daily doses of 17-AAG (20mg/kg, 40mg/kg, 80mg/kg) or vehicle only (control) on tumour volume in MMTV-NEU-NT transgenic mice. Tumour volume expressed as a % of day 0 (column 2), p values: day 4 vs day 0. Tumour volume also expressed as a % of control cohort at day 4 (column 4), p values: treated day 4 vs control day 4. Mean tumour volume at day 0 of the 4 cohorts was 0.59 ± 0.08 cm3 (control), 0.67 ± 0.07 cm3 (20mg/kg), 0.67 ± 0.08 cm3 (40mg/kg) and 0.61 ± 0.12 cm3 (80mg/kg). Data are presented as the mean ± SEM.